Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
severe fever with thrombocytopenia syndrome virus vaccine
- Development stage
- Preclinical
- Lead developer
- Phylex BioSciences
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Intramuscular
01
Overview
The severe fever with thrombocytopenia syndrome (SFTS) virus vaccine is an investigational mRNA-based vaccine being developed by Phylex BioSciences. It is designed to prevent SFTS, a tick-borne viral disease caused by the SFTS virus (SFTSV, also known as Dabie bandavirus), which is associated with high case-fatality rates and is endemic in parts of East Asia including China, South Korea, Japan, and Vietnam. The vaccine utilizes Phylex's proprietary self-assembling nanoparticle (SANP) platform, which displays viral antigens—likely the Gn/Gc surface glycoproteins and/or nucleoprotein—on a nanoparticle surface to elicit a potent immune response. The program is currently in the preclinical stage of development.
- Other names
- SFTS virus vaccineSFTS vaccineSevere fever with thrombocytopenia syndrome vaccine
02
Targets
Severe fever with thrombocytopenia syndrome virus Gc glycoproteinSFTSV Gn (Severe fever with thrombocytopenia syndrome virus glycoprotein Gn)
Beyond the preview
Go deeper on severe fever with thrombocytopenia syndrome virus vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on severe fever with thrombocytopenia syndrome virus vaccine.